Immunome, Inc. Hits Day High with 15.96% Surge in Stock Price

Immunome, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant activity today, gaining 15.96% as of October 15, 2025. The stock reached an intraday high of USD 16.40, reflecting a strong performance compared to the S&P 500, which saw a slight decline of 0.16% on the same day.
Over the past week, Immunome has shown a robust increase of 16.7%, and its one-month performance stands at an impressive 72.47%. Year-to-date, the stock has risen by 53.95%, significantly outperforming the S&P 500's 12.97% gain. Notably, the company has reported a net profit of USD -85.04 million for the half-year, marking a turnaround after five consecutive quarters of losses.

Immunome's return on capital employed (ROCE) has reached its highest at -81.2%, while raw material costs have decreased by 14.94% year-over-year. The company boasts high institutional holdings at 100%, indicating strong confidence from institutional investors. With consistent returns over the last three years, Immunome continues to demonstrate resilience in a competitive market.